Gad H, et al. – Via performing this systematic review and meta-analysis, researchers assessed the benefits and risks of continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) in patients with type 1 diabetes mellitus (T1DM) fasting during Ramadan. A total of nine relevant studies—identified via a search of electronic databases—were included in the final analysis. In all, the investigators did not identify any significant differences for change in glycemic control between CSII and MDI, and there was no weight change or change in the lipid profile in patients with T1DM on MDI during Ramadan. Data were insufficient to evaluate the effect on glucose profiles and hypoglycemia incidence or incidence of diabetic ketoacidosis in patients on CSII or MDI during Ramadan. Overall, trials investigating the impact of CSII or MDI in type 1 diabetic patients who choose to fast during Ramadan are limited to observational studies, and these studies did not indicate any difference in the change in glycemic control, weight, or lipids during the time frame of this holiday.